Quarterly Report · 10-Q

Amphastar Pharmaceuticals, Inc.

AMPHNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 6, 2026Accepted Aug 6, 2026, 4:50 PM EDTCIK 1297184Accession 0001297184-26-000047

Company context

Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company’s finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.

Current securities

AMPHNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Amphastar Pharmaceuticals, Inc. · 10-Q · Filed 2026-08-06

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol: AMPH
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: Duration_1_1_2026_To_6_30_2026_q4rlp0dYFUm9mPVCDY7W7g

Dimensions: Not supplied

Accession 000129718426000047 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.